I'm not sure how this links to GB-A, that is, whether the hospitals can get funding from the Statutory Health Funds without GB-A approval.
But it highlights the scale of the opportunity and relatively rapid uptake.
If 84 hospitals do 5 each a year, that's over 400 implants. At current price it's around 8 million in revenue.
I think the Turkish distributor putting Oncosil in the same category as Lutetium treatment is very positive.
Ann: 84 German hospitals can negotiate fee for Oncosil device, page-2
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.001(8.33%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.3¢ | 1.2¢ | $45.97K | 3.729M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 3583333 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 11196398 | 10 |
View Market Depth
| Last trade - 15.31pm 09/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |